Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Respiratory Syncytial Virus Infection Pipeline: Insights into Clinical Trial Landscape, Key Pharma Players, Emerging Therapies with Novel MoAs, and Dynamics Shaping the Pipeline Landscape | DelveInsight

Published

on

Los Angeles, USA, Aug. 02, 2021 (GLOBE NEWSWIRE) — Respiratory Syncytial Virus Infection Pipeline: Insights into Clinical Trial Landscape, Key Pharma Players, Emerging Therapies with Novel MoAs, and Dynamics Shaping the Pipeline Landscape | DelveInsight

A vaccine in the Respiratory Syncytial Virus Infection Pipeline presents a cost-effective solution to reducing the burden of RSV, as current options for both prevention and treatment are limited with currently no licensed vaccines available.

DelveInsight’s ‘Respiratory Syncytial Virus (RSV) Infection Pipeline Insights report provides exhaustive global coverage of the available therapies, Respiratory Syncytial Virus drug profiles, emerging therapies in different phases of clinical development, key companies working to advance the Respiratory Syncytial Virus Infection Pipeline drugs, and future potential of the Respiratory Syncytial Virus Infection Pipeline domain. It also includes the Respiratory Syncytial Virus therapeutics assessment by product type, stage, mechanism of action, and molecule type.

Some of the significant pointers taken from the Respiratory Syncytial Virus Infection Pipeline report:

  • DelveInsight’s analysis depicts a robust Respiratory Syncytial Virus Infection Pipeline with 50+ active players in the domain working on 50+ pipeline therapies.
  • Key Respiratory Syncytial Virus Infection Pipeline therapies such as RSV-F, V-306, CodaVax-RSV, mRNA-1345, MV-012-968, RV521, BARS13, EDP-938, MEDI8897, RSV MAT, RSVpreF, JNJ-53718678, RSV vaccine, ALVR106, V-306, CodaVax-RSV, mRNA-1345, Research program: sirtuin targeted therapeutics for respiratory viral infections and others are under different phases of clinical trials for Respiratory Syncytial Virus (RSV).
  • Virometix, ReViral Ltd, Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. Codagenix, Inc, ModernaTX, Inc., Meissa Vaccines, Inc., Vaxart, Inc., Enanta Pharmaceuticals, MedImmune LLC (AstraZeneca), GlaxoSmithKline, Pfizer, Janssen Sciences Ireland UC, Icosavax, Inc., Ark Biosciences, Bavarian Nordic, Kidswell Bio, Evrys Bio, ReViral Ltd, Sanofi, Daiichi Sankyo, Codagenix, Inc., Cidara Therapeutics, clover biopharmaceuticals, Alios BioPharma, Allovir, Airway Therapeutics, and others are under different phases of clinical trials for Respiratory Syncytial Virus. 
  • The RSVpreF (Pfizer) vaccine candidate is based on the prefusion form of the RSV fusion protein. The vaccine works by stimulating the production of serum anti-F immunoglobulin G in the pregnant woman, which is transferred to the fetus across the placenta and provides protection for the first six months of life when the risk of hospitalization is highest.
  • Enanta has selected EDP-938, a potent non-fusion inhibitor of both RSV-A and RSV-B activity, as its first development candidate for RSV. 
  • IVX-121 and IVX-A12 are the two vaccine candidates being developed by Icosavax, Inc. IVX-121 target Respiratory Syncytial Virus, a major cause of viral pneumonia for which no vaccine has been FDA approved.
  • ResVax is our aluminum-adjuvanted RSV F vaccine for infants via maternal immunization. The Bill & Melinda Gates Foundation (BMGF) has supported the Prepare trial for ResVax through a grant of up to $89.1 million; BMGF continues to financially support our efforts to conduct certain follow-up analyses of the Phase III data.
  • In October 2020, Moderna, Inc., regained all rights to the respiratory syncytial virus (RSV) vaccine (mRNA-1172) from Merck, known as MSD outside the United States and Canada, including rights to develop RSV vaccines for adult populations. mRNA-1172, which uses a Merck lipid nanoparticle for delivery, entered Phase 1 development in 2019. Under the terms of the agreement, Merck will complete the Phase 1 study and transition the program to Moderna.
  • The development of V-306 Virometix offers a differentiated approach to RSV vaccine development. In Phase I clinical trial, V-306 demonstrated strong, durable, specific, and protective immune responses, with minimal risk of vaccine-associated enhanced respiratory disease.
  • Meissa is developing MV-012-968, an intranasal (needle-free), adjuvant-free, live-attenuated vaccine candidate, to protect infants and at-risk older adults from RSV. MV-012-968 is currently in a Phase IIa, randomized, double-blind, placebo-controlled challenge study designed to evaluate the safety and prophylactic efficacy of the Meissa vaccine against symptomatic RSV infection

Request Sample to know more about the pipeline therapies @ Respiratory Syncytial Virus Infection Pipeline Insights

The Respiratory Syncytial Virus Infection Pipeline report offers comprehensive insights into the assessment of active pipeline products, inactive products analysis (dormant and terminated), comparative analysis of clinical and non-clinical stage RSV products, and understanding of the limitations and challenges with regard to the development of therapies for Respiratory Syncytial Virus.

Respiratory Syncytial Virus Overview 

Respiratory Syncytial Virus causes respiratory infections throughout life, with infants in the first months of life, severely immune-compromised adults, and the elderly especially susceptible to developing severe lower respiratory tract disease or death. The virus is the most common cause of lower respiratory tract infections (LRTI) and the leading viral cause of severe lower respiratory tract disease in infants and young children globally.

Learn more about the disease, treatments, and pipeline therapies @ Respiratory Syncytial Virus Infection Pipeline Assessment 

Respiratory Syncytial Virus Infection Pipeline Drugs

Drug Company Phase MoA RoA
RSV-F Novavax III Immunostimulants Intramuscular
MEDI8897 MedImmune LLC
(AstraZeneca)
III Immunostimulants Intramuscular
RSVpreF Pfizer III Immunostimulants Intramuscular
JNJ-53718678 Janssen
Sciences Ireland UC
III Viral fusion protein inhibitors Oral
RSV MAT GlaxoSmithKline III Immunostimulants Intramuscular
MV-012-968 Meissa
Vaccines, Inc.
II Immunostimulants Intranasal
RV521 ReViral Ltd II Viral fusion protein inhibitors; Virus replication inhibitors Oral
BARS13 Advaccine (Suzhou)
Biopharmaceuticals Co., Ltd.
II Immunostimulants Intramuscular
EDP-938 Enanta
Pharmaceuticals
II Viral fusion protein inhibitors Oral
MVA-mBN294B Bavarian Nordic II Immunostimulants Intramuscular
RSV vaccine Sanofi I/II Immunostimulants Intranasal
ALVR106 Allovir I/II Immunologic cytotoxicity; T lymphocyte replacements NA
V-306 Virometix I Immunostimulants Intramuscular
CodaVax-RSV Codagenix, Inc I CD8 positive T lymphocyte stimulants; Immunostimulants Intranasal
mRNA-1345 ModernaTX, Inc. I Immunostimulants NA
Research programme: sirtuin targeted therapeutics for respiratory viral infections Evrys Bio Preclinical Sirtuin modulators Oral

Request for Sample to know more @ Respiratory Syncytial Virus Infection Pipeline Analysis, Key Companies, and Futuristic Trends

Respiratory Syncytial Virus Therapeutic Assessment

The Respiratory Syncytial Virus Infection Pipeline report presents a complete view of the Respiratory Syncytial Virus emerging novel pipeline therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

  • Mono
  • Combination

By Stage

  • Discovery 
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Molecule Type 

  • Gene therapy
  • Stem cell therapy
  • Small molecules

By Route of Administration

  • Oral
  • Intravenous
  • Inhalation
  • Subcutaneous

By Mechanism of Action

  • Protease Inhibitors
  • Immunomodulatory
  • Immunostimulants
  • Sirtuin modulators
  • Immunologic cytotoxicity; T lymphocyte replacements
  • CD8 positive T lymphocyte stimulants
  • Viral fusion protein inhibitors

By Targets

  • Protease Inhibitors
  • Immune system

Scope of Respiratory Syncytial Virus Infection Pipeline Report 

  • Coverage: Global 
  • Major Players: 50+ Key Players
  • Prominent Players: Virometix, ReViral Ltd, Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. Codagenix, Inc, ModernaTX, Inc., Meissa Vaccines, Inc., Vaxart, Inc., Enanta Pharmaceuticals, MedImmune LLC (AstraZeneca), GlaxoSmithKline, Pfizer, Janssen Sciences Ireland UC, Icosavax, Inc., Ark Biosciences, Bavarian Nordic, Kidswell Bio, Evrys Bio, ReViral Ltd, Sanofi, Daiichi Sankyo, Codagenix, Inc., Cidara Therapeutics, clover biopharmaceuticals, Alios BioPharma, Allovir, Airway Therapeutics, and others.
  • Key Respiratory Syncytial Virus Infection Pipeline Therapies: RSV-F, V-306, CodaVax-RSV, mRNA-1345, MV-012-968, RV521, BARS13, EDP-938, MEDI8897, RSV MAT, RSVpreF, JNJ-53718678, RSV vaccine, ALVR106, V-306, CodaVax-RSV, mRNA-1345, Research program: sirtuin targeted therapeutics for respiratory viral infections and others.

Dive deeper into Respiratory Syncytial Virus Infection Pipeline Emerging Therapies, Treatments, and Ongoing Clinical Trials

Table of Contents 

1 Introduction
2 Executive Summary
3 Respiratory Syncytial Virus Overview
4 RSV Analytical Perspective In-depth Commercial Assessment
5 Pipeline Therapeutics
6 Late Stage Products (Phase III)
7 Mid Stage Products (Phase II)
8 Early Stage Products (Phase I)
9 Therapeutic Assessment
10 Inactive Products
11 Company-University Collaborations (Licensing/Partnering) Analysis
12 Respiratory Syncytial Virus Infection Key Companies
13 Respiratory Syncytial Virus Infection Key Products
14 Respiratory Syncytial Virus Infection Unmet Needs
15 Respiratory Syncytial Virus Infection Market Drivers and Barriers
16 RSV Infection Future Perspectives and Conclusion
17 Respiratory Syncytial Virus: Analyst Views
18 Appendix
19 About DelveInsight

Learn more about the report offerings @ Respiratory Syncytial Virus Drug Pipeline Therapies, Novel Drug Delivery Platforms, and Emerging Trends

Audit the market before venturing with DelveInsight’s Due Diligence Services  

Related Reports
Respiratory Syncytial Virus Market
DelveInsight’s “Respiratory Syncytial Virus (RSV) Market Insight, Epidemiology and Market Forecast -2031” report.

Respiratory Distress Market
DelveInsight’s “Acute respiratory distress syndrome (ARDS) – Pipeline Insights, 2021” report

Severe Acute Respiratory Syndrome (SARS) Coronavirus Market
DelveInsight’s  “Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection – Market Insights, Epidemiology, and Market Forecast-2030” report 

Middle East Respiratory Market
DelveInsight’s  “Middle East Respiratory Syndrome – Pipeline Insight, 2021” report.

Bacterial Vaginosis Market
DelveInsight’s “Bacterial Vaginosis – Market Insights, Epidemiology, and Market Forecast-2030” report.

Candidemia Market
DelveInsight’s ‘Candidemia – Market Insights, Epidemiology, and Market Forecast—2030’ report.

Browse through our Blog Posts

Artificial intelligence and robotics are the two technologies that have shown the potential to address and provide solutions to many contemporary issues. Over the past three-four decades, robots have been used in sectors such as laboratory research, earth and space exploration, transport, and many more.

With at least half of the world’s population as women and over 100 startups leveraging technology to bring novel devices to help women through different biological stages such as menstruation, pregnancy, breastfeeding, and others, the FemTech market offers ample growth opportunities.

The contribution of key pharma companies, such as 9 Meters Biopharma, ImmunogenX, Provention Bio, Cour Pharmaceuticals/Takeda, Precigen ActoBio, Falk Pharma, and Zedira is significant in driving Celiac disease market size. 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Aurionpro Solutions acquires Arya.ai, to power next generation Enterprise AI platforms for Financial Institutions

Published

on

aurionpro-solutions-acquires-arya.ai,-to-power-next-generation-enterprise-ai-platforms-for-financial-institutions

SINGAPORE, April 20, 2024 /PRNewswire/ — Aurionpro Solutions Limited (BSE: 532668) (NSE: AURIONPRO) announces the acquisition of Banking and Insurance focused PaaS startup, Arya.ai. With Arya.ai, Aurionpro will enhance its portfolio of enterprise fintech offerings to expedite adoption of AI that is responsible, accurate, and auditable.

 
 
Aurionpro Solutions Ltd. will acquire a majority stake (67%) in Arya.ai. This acquisition will bring products and expertise in Artificial Intelligence, Deep Learning, Intelligent Automation, PaaS, Autonomous AI Platforms, and more, to complement and strengthen Aurionpro’s industry leading portfolio.
The transaction comprises acquisition of shares held by the existing shareholders and subscription of new equity capital in the company. This will be an all-cash deal. The aggregate investment including  secondary acquisition and fund infusion is approximately 16.5 MN USD.
By integrating Arya.ai’s cutting-edge AI cloud platform, with Aurionpro’s comprehensive suite of offerings, the company will create an industry leading Enterprise AI platform focused on creating value for financial institutions globally. 
Commenting on the acquisition, Ashish Rai, CEO of Aurionpro Solutions, stated, “The acquisition of Arya.ai marries Aurionpro’s portfolio of industry leading enterprise software with one of the most mature Enterprise AI platforms focused on Banks and Insurers. We are incredibly excited about working with Arya.ai and our wider ecosystem partners to build out the leading Enterprise AI platform, for the financial industry worldwide.”
“Our decade long experience in building tools/platform for deep learning helped us to build a truly verticalized AI Operating System for Banking and Insurance.” Says Vinay Kumar CEO/Founder of Arya.ai. “Together with Aurionpro, we are going to build a new generation of Enterprise AI software for Banks and Insurers that truly embeds AI, augmenting a task or Autonomous Agents that can take over entire transactions”. 
Founded in 2013 by Vinay Kumar and Deekshith Marla, Arya.ai has been one of the first ‘AI’ startups to use Deep Learning and deploy in enterprises. Arya.ai’s BFSI PaaS offerings include Arya API with 80+ ML models, Libra for fine-tuning SOTA ML models, and AryaXAI for AI governance.
Photo – https://mma.prnewswire.com/media/2392705/Aurionpro_solutions.jpgLogo – https://mma.prnewswire.com/media/2392706/Aurionpro_Logo.jpg
 
 

View original content:https://www.prnewswire.co.uk/news-releases/aurionpro-solutions-acquires-aryaai-to-power-next-generation-enterprise-ai-platforms-for-financial-institutions-302122674.html

Continue Reading

Artificial Intelligence

Free Your Hands, QIDI Vida Smart AR Glasses Lead the Way in New Sports Experience.

Published

on

free-your-hands,-qidi-vida-smart-ar-glasses-lead-the-way-in-new-sports-experience.

NEW YORK, April 19, 2024 /PRNewswire/ — Outdoor smart AR glasses, QIDI Vida, will officially launch on 23rd April on the Kickstarter platform.  QIDI Vida integrates the many functions of smart watches, sports headphones, cycling computers, heart rate monitors, and walkie-talkies using AR+AI technology, allowing users to bid farewell to cumbersome device management and enjoy outdoor sports anytime, anywhere with just one pair of glasses.

 
Function:
QIDI Vida uses high-tech HUD (Head-Up Display) which is similar to the technology used for aircrafts and premium cars and introduces it to the sports industry. Users can activate the HUD function at any time using voice control, enabling them to focus on the route ahead whilst simultaneously having access to information such as navigation, speed, heart rate, power and cadence, among other metrics. Another great function of the QIDI Vida is that users can also enjoy audiovisual entertainment through the optically perceived 100-inch AR  HUD screen, when having some down time. 
As cyclists and hikers often travel in groups, QIDI Vida supports eSIM and team functionality, allowing real-time voice communication without releasing handlebars, and users can monitor their groups’ real-time locations. The glasses also have comprehensive sensing and monitoring capabilities including temperature, humidity, UV, air pressure, geomagnetism and acceleration. In addition to obtaining environmental and health information, it also features health warnings such as altitude sickness symptoms and high heart rate, as well as fall and collision detection functions. And, in the event of danger, it can send distress signals to teammates.
Perks:
QIDI Vida has a global voice recognition and interaction feature that allows you to control all functions within the device by voice. To better provide users with an immersive sports experience, QIDI Vida’s intelligent system will have the capability to instantly gather personalised sports data, enabling it to deliver timely voice alerts and broadcasts, including the duration of exercise, distance, the environment and the weather – all tailored to the user’s preferences.
QIDI Vida enables voice-controlled photos and video recordings, allowing users to capture moments whilst cycling or hiking without the need to stop. QIDI Vida supports connections with common cycling smart hardware such as Garmin, Wahoo, Apple, and Samsung, supports GPX route files, and is compatible with professional sports apps such as Strava, Keep, Zwift, Apple Health, and All Trails.
QIDI Vida stands out for its lightweight and comfortable design with a dual lens for a full-colour data display, unlike competing AR glasses that typically have a single lens and limited colour. This innovation significantly enhances and augments the user’s sports and reality experience.
QIDI Vida will launch on the Kickstarter platform: https://www.kickstarter.com/projects/109560964/qidi-vida-smart-ar-glasses-for-sports
HIGH RES IMAGE: https://we.tl/t-epx2syiuaRWATCH VIDEO: https://www.youtube.com/watch?v=2v_Pli2pAM8&t=164s
Photo – https://mma.prnewswire.com/media/2392090/2.jpgPhoto – https://mma.prnewswire.com/media/2392092/3.jpgPhoto – https://mma.prnewswire.com/media/2392093/4.jpgPhoto – https://mma.prnewswire.com/media/2392089/1_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/free-your-hands-qidi-vida-smart-ar-glasses-lead-the-way-in-new-sports-experience-302122189.html

Continue Reading

Artificial Intelligence

Risk Analytics Market worth $180.9 billion by 2029 – Exclusive Report by MarketsandMarkets™

Published

on

risk-analytics-market-worth-$180.9-billion-by-2029-–-exclusive-report-by-marketsandmarkets™

CHICAGO, April 19, 2024 /PRNewswire/ — The growing use of real-time monitoring and advanced analytics, integration with cutting-edge technologies like blockchain and IoT, and an emphasis on cybersecurity, cross-industry applications, and regulatory compliance are the key factors that will shape the risk analytics market in the future. The market’s development will also be influenced by collaborative risk management, improved user experience, and an increasing focus on ESG factors and risk culture.

The Risk Analytics Market is estimated to grow from USD 59.7 billion in 2024 to USD 180.9 billion in 2029, at a CAGR of 24.8% during the forecast period, according to a new report by MarketsandMarkets™.  Several trends fuel the global spread of Risk Analytics. Increasingly Increasing Data Complexity, Rising Cybersecurity Threats and Rising Adoption of Cloud-Based Solutions A growing talent pool of data scientists and engineers is building the necessary tools and infrastructure. Governments are recognizing the potential of risk analytics for economic growth and are investing in research and development. These trends make DI more accessible and valuable, leading to its global adoption.
Browse in-depth TOC on “Risk Analytics Market”260 – Tables 60 – Figures350 – Pages
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210662258
Scope of the Report
Report Metrics
Details
Market size available for years
2019–2023
Base year considered
2023
Forecast period
2024–2029
Forecast units
USD Billion
Segments Covered
Offering,Risk Type, Risk stages, Vertical, and Region.
Geographies covered
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America
Companies covered
IBM (US), SAS Institute (US), Oracle (US), FIS(US), Moody’s Analytics (US), ProcessUnity(US), ServiceNow (US), Marsh (US), Aon (UK), MetricStream (US), Resolver (Canada), SAP (Germany), Milliman(US), LogicManager(US), Provenir(US), SAI360(US), Deloitte(UK), OneTrust(US), Diligent(US), Alteryx(US), CRISIL(India), Archer(US), ZestyAI(US), Fusion Risk Management(US), RiskVille(Ireland), SPIN Analytics(UK), Kyvos Insights(US), Imperva(US), Cirium(UK), Quantexa(UK), ClickUp(US), Sprinto(US), Ventiv(US), Adenza(US), Centrl.AI(Canada), SafetyCulture(Australia), Quantifi(US), CubeLogic(UK), Onspring(US), Riskoptics(US)
 
By offering the services segment to account for higher CAGR during the forecast period
In the Risk Analytics Market, the highest CAGR of services is fueled by Increasing Complexity of Risks, AI and machine learning advancements, big data analytics integration, business process optimization, cloud-based solutions adoption, data-driven culture, and diverse industry adoption. These trends reflect a global shift towards leveraging data for competitive advantage, driving a continuous need for sophisticated risk analytics services across sectors. As businesses prioritize agility, the growth of services in the Risk Analytics Market is driven by the need for effective risk management strategies in an increasingly complex and uncertain business environment.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=210662258
By Type, GRC software is expected to hold the largest market size for the year 2024
GRC software typically offers comprehensive solutions that cover a wide range of risk management needs, including compliance management, policy management, audit management, and risk assessment. They also provide organizations with enhanced visibility into their risk landscape. Through features such as risk assessment, risk monitoring, and reporting, organizations can identify and prioritize risks more effectively, enabling proactive risk management strategies.  GRC software streamlines risk management processes through automation, reducing manual effort and increasing efficiency. Tasks such as risk assessments, control testing, and incident management can be automated, freeing up resources to focus on strategic risk mitigation efforts. the combination of comprehensive functionality, regulatory compliance support, efficiency gains, scalability, integration capabilities, and culture enhancement makes GRC software a preferred choice for many organizations seeking to manage risk effectively.
By Vertical, Healthcare & Life Sciences is projected to grow at the highest CAGR during the forecast period
The Healthcare and Lifesciences is experiencing a surge in the adoption of risk analytics due to a confluence of factors. Healthcare providers and life sciences companies wants to ensure the safety and well-being of patients. Risk analytics helps in identifying potential risks to patient safety, such as medication errors, adverse events, and medical device failures. The healthcare and life sciences industries are heavily regulated, with strict guidelines for patient care, data privacy, drug development, and clinical trials. Risk analytics helps organizations ensure compliance with these regulations by identifying and mitigating risks of non-compliance.  Healthcare organizations and life sciences companies also face financial risks associated with fraud, billing errors, revenue cycle management, and reimbursement challenges. Risk analytics helps in detecting anomalies and optimizing financial processes to mitigate these risks.
Asia Pacific is expected to grow at the highest CAGR during the forecast period
The Asia-Pacific (APAC) region is experiencing rapid growth in the Risk Analytics Market, boasting the highest Compound Annual Growth Rate (CAGR). This surge is primarily attributed to rising demand for data-driven decision-making solutions, expanding digital transformation initiatives across industries.. Moreover, the region’s favorable regulatory environment, growing investments in big data analytics, and the integration of advanced technologies like the Internet of Things (IoT) further propel APAC’s dominance in Risk Analytics Market growth.
Top Key Companies in Risk Analytics Market:
The major risk analytics software and service providers include IBM (US), SAS Institute (US), Oracle (US), FIS(US), Moody’s Analytics (US), ProcessUnity(US), ServiceNow (US), Marsh (US), Aon (UK), MetricStream (US), Resolver (Canada), SAP (Germany), Milliman(US), LogicManager(US), Provenir(US), SAI360(US), Deloitte(UK), OneTrust(US), Diligent(US), Alteryx(US), CRISIL(India), Archer(US), ZestyAI(US), Fusion Risk Management(US), RiskVille(Ireland), SPIN Analytics(UK), Kyvos Insights(US), Imperva(US), Cirium(UK), Quantexa(UK), ClickUp(US), Sprinto(US), Ventiv(US), Adenza(US), Centrl.AI(Canada), SafetyCulture(Australia), Quantifi(US), CubeLogic(UK), Onspring(US), Riskoptics(US). These companies have used both organic and inorganic growth strategies such as product launches, acquisitions, and partnerships to strengthen their position in the Risk Analytics Market.
Recent Developments:
In March 2024, Orcale announced Oracle Risk Management Cloud in Release 24B. It offers comprehensive solution designed to help organizations identify, assess, and mitigate risks across their business operations. It offers advanced analytics, automation, and collaboration tools to streamline risk management.In March 2024, FIS Global announces card fraud detection capabilities leveraging artificial intelligence (AI) with aim to bolster FIS’s ability to identify and prevent fraudulent transactions, providing greater security for cardholders and financial institutions alike.In March 2024, Aon acquired an AI-powered platform to assist fleet and mobility clients in making data-driven decisions, enhancing operational efficiency and risk management. The platform utilizes artificial intelligence to analyze data and provide insights, enabling clients to optimize their fleet operations and improve decision-making processes.In March 2024, Crisp joined Resolver, with the aim to enhance Resolver’s risk intelligence capabilities by integrating Crisp’s expertise and technology into its platform, offering clients improved risk assessment and mitigation tools.In February 2024, SAS partnered with Carahsoft to bring analytics, AI, and data management solutions to the public sector. The aim is to leverage SAS’s expertise in advanced analytics and Carahsoft’s extensive government market reach to offer tailored solutions that enable public sector organizations to harness the power of data for informed decision-making and improved outcomes.Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=210662258
Risk Analytics Market Advantages:
By offering insights into potential risks, opportunities, and trends, risk analytics helps organisations make data-driven decisions that improve strategic planning and resource allocation.In order to improve risk management procedures and lessen exposure to possible threats, risk analytics solutions assist businesses in identifying, evaluating, and mitigating risks across a range of business activities, including finance, operations, and compliance.Through real-time monitoring and anomaly detection made possible by risk analytics, organisations may proactively address shifting market situations, legal requirements, and cybersecurity threats.Risk analytics solutions assist organisations lower operating costs, increase productivity, and streamline compliance activities, which results in cost savings and resource optimisation. They do this by streamlining risk management procedures and automating routine work.Accurate risk assessments, audit trails, and reporting capabilities are just a few of the ways that risk analytics solutions help organisations comply with regulations and stay out of trouble.Organisations can enhance their resilience and competitiveness by anticipating and mitigating potential hazards before they materialise through the use of predictive modelling and advanced analytics approaches in risk analytics.Report Objectives
To define, describe, and predict the Risk Analytics Market by offering, risk type, risk stages, vertical, and regionTo provide detailed information about the major factors (drivers, restraints, opportunities, and challenges) influencing the market growthTo analyze the opportunities in the market and provide details of the competitive landscape for stakeholders and market leadersTo forecast the market size of segments with respect to five main regions: North America, Europe, Asia Pacific, Middle East & Africa, and Latin AmericaTo profile the key players and comprehensively analyze their market rankings and core competenciesTo analyze the competitive developments, such as partnerships, product launches, and mergers & acquisitions, in the Risk Analytics MarketBrowse Adjacent Markets: Analytics Market Research Reports & Consulting
Related Reports:
Customer Data Platform Market – Global Forecast to 2028
Speech Analytics Market- Global Forecast to 2029
Text to Video AI Market – Global Forecast to 2027
Contact Center Analytics Market- Global Forecast to 2027
Procurement Analytics Market- Global Forecast to 2026
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:Mr. Aashish MehraMarketsandMarkets™ INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Insight: https://www.marketsandmarkets.com/ResearchInsight/risk-analytics-market.aspVisit Our Website: https://www.marketsandmarkets.com/Content Source: https://www.marketsandmarkets.com/PressReleases/risk-analytics.asp
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/risk-analytics-market-worth-180-9-billion-by-2029—exclusive-report-by-marketsandmarkets-302121085.html

Continue Reading

Trending